Ribomic

Ribomic Acquisitions (Net)

The Acquisitions (Net) of Ribomic (4591.T) as of Oct 30, 2026 is 100.00 M JPY. In the previous year, Acquisitions (Net) was 200.00 M JPY — a change of -50.00% (lower).

Acquisitions (Net)

100.00 MJPY

YoY

-50.00%

Last updated:

Acquisitions (Net) of Ribomic is 2025 100.00 M JPY. Acquisitions (Net) of Ribomic was 2024 200.00 M JPY. It decreases by -50.00% lower compared to the previous year.

The Ribomic Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2018
973.66 M JPY
Jan 1, 2019
-400.10 M JPY
Jan 1, 2020
599.90 M JPY
Jan 1, 2021
-1.70 B JPY
Jan 1, 2022
700.00 M JPY
Jan 1, 2023
300.28 M JPY
Jan 1, 2024
200.00 M JPY
Jan 1, 2025
100.00 M JPY
The Ribomic Acquisitions (Net) history
YEARAcquisitions (Net)YoY
100.00 MJPY-50.00%
200.00 MJPY-33.40%
300.28 MJPY-57.10%
700.00 MJPY-141.22%
-1.70 BJPY-383.11%
599.90 MJPY-249.94%
-400.10 MJPY-141.09%
973.66 MJPY+56.00%
624.13 MJPY-147.48%
-1.31 BJPY+1.11%
-1.30 BJPY-1,400.00%
100.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

Acquisitions (Net) of Ribomic is 100.00 M JPY in 2025.

Acquisitions (Net) of Ribomic changed from 200.00 M JPY to 100.00 M JPY, representing a -50.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) Ribomic since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s Ribomic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Ribomic

All Key Metrics — Ribomic